The mutations are mostly heterozygous and inactivating (e.g., deletions and missense mutations that are predicted to disrupt its DNA-binding domain), suggesting that BCL11B may be a haploinsufficient tumor suppressor in T-ALL. Here, BCL11B is linked to acute lymphoblastic leukemia.